SaNOtize Research and Development Corp. is a Vancouver-based pharmaceutical and medical-device company that harnesses nitric oxide (NO), a naturally occurring antimicrobial molecule, to prevent and treat viral, bacterial and fungal infections. Its patented Nitric Oxide Releasing Solution (NORS) platform powers a Nitric Oxide Nasal Spray (NONS) sold internationally under brands including Enovid, VirX and FabiSpray, along with a pipeline addressing COVID-19, respiratory viruses, sinusitis, wound infection and onychomycosis.
Mikael Svensson is Chief Executive Officer of SaNOtize Research and Development Corp., the Vancouver-based company commercializing nitric oxide as an antimicrobial platform, most recently through its NOWONDER consumer nasal cleanser. A chemical engineer by training with more than two decades in medical device and pharmaceutical commercialization, he previously led the global launch of INOmax inhaled nitric oxide therapy and worldwide expansion work on Restylane, Naftin, Mederma and VagiVital.